{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:23:33Z","timestamp":1777998213483,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2020Y9070"],"award-info":[{"award-number":["2020Y9070"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2018Y9037"],"award-info":[{"award-number":["2018Y9037"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2021R0053"],"award-info":[{"award-number":["2021R0053"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>This study evaluated the cost-effectiveness of nivolumab plus ipilimumab (NI) versus pemetrexed plus cisplatin\/carboplatin (C) as the first-line treatment for unresectable malignant pleural mesothelioma (MPM) from the perspective of US payers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A 10-year partitioned survival model was constructed using survival and safety data from the CheckMate 743 clinical trial. The output metrics of the model included the patient\u2019s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). Only direct medical costs were considered. One-way and probabilistic sensitivity analyses were conducted to assess the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among all randomized patients, group NI had an ICER of $475,677\/QALY relative to group C. Among patients with epithelioid histology, group NI had an ICER of $760,955\/QALY. Among patients with non-epithelioid histology, group NI had an ICER of $418,348\/QALY. The ICERs of all three populations exceeded the willingness-to-pay threshold ($150,000). The results of one-way sensitivity analysis revealed that the cost of nivolumab had a great influence on the results. The results of probabilistic sensitivity analysis demonstrated that the possibility of NI being more economical in all randomized patients and in patients with non-epidemiology histology was 0. In patients with epithelioid histology, the probability that NI had an economic advantage was 0.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>From the perspective of US payers, in patients with unresectable MPM, NI has no economic advantage over C.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359221116604","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T08:45:27Z","timestamp":1659516327000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness analysis of nivolumab plus ipilimumab\n                    <i>versus<\/i>\n                    chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma"],"prefix":"10.1177","volume":"14","author":[{"given":"Liu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Xinquan Road 29, Fuzhou 350100, China"},{"name":"Fujian Medical University, Fuzhou, China"},{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-4882","authenticated-orcid":false,"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Xinquan Road 29, Fuzhou 350100, China"},{"name":"Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"bibr1-17588359221116604","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.08.19"},{"key":"bibr2-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.011"},{"key":"bibr3-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"bibr4-17588359221116604","first-page":"1","volume":"58","author":"Opitz I","year":"2020","journal-title":"Eur Respir J"},{"key":"bibr5-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c73d6"},{"key":"bibr6-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c73ec"},{"key":"bibr7-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"bibr8-17588359221116604","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck JP","year":"2005","journal-title":"J Clin Oncol"},{"key":"bibr9-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"bibr10-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"bibr11-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"bibr12-17588359221116604","unstructured":"NCCN. NCCN guidelines, (2022). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1id=1442 (accessed 21 March 2022)."},{"key":"bibr13-17588359221116604","unstructured":"Centers for Medicare and Medicaid Services. ASP drug pricing files, (2022). https:\/\/www.cms.gov (accessed 21 March 2022)."},{"key":"bibr14-17588359221116604","first-page":"1","volume":"70","author":"Arias E","year":"2022","journal-title":"Natl Vital Stat Rep"},{"key":"bibr15-17588359221116604","unstructured":"Centers for Disease Control and Prevention, (2022). https:\/\/www.cdc.gov\/nchs\/nvss\/life-expectancy.htm#publications (accessed 23 March 2022)."},{"key":"bibr16-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00987-3"},{"key":"bibr17-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"bibr18-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"bibr19-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"bibr20-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1186\/s12942-021-00276-y"},{"key":"bibr21-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4904"},{"key":"bibr22-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2278"},{"key":"bibr23-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"bibr24-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32368"},{"key":"bibr25-17588359221116604","unstructured":"Centers for Medicare and Medicaid Services. CY 2022 Medicare physician fee schedule (PFS) final rule, (2022). https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched (accessed 21 March 2022)."},{"key":"bibr26-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8787"},{"key":"bibr27-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.004"},{"key":"bibr28-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.03.006"},{"key":"bibr29-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.05.012"},{"key":"bibr30-17588359221116604","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.641975"},{"key":"bibr31-17588359221116604","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.07.011"},{"key":"bibr32-17588359221116604","doi-asserted-by":"publisher","DOI":"10.3310\/hta11010"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221116604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359221116604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221116604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:27:31Z","timestamp":1777588051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359221116604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"alternative-id":["10.1177\/17588359221116604"],"URL":"https:\/\/doi.org\/10.1177\/17588359221116604","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17588359221116604"}}